1204669-69-1 Usage
Description
(Ν-(2-((4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-yl)amino)ethyl)tert-butylsulfamoyl)carbamate is a complex organic compound with a diverse array of functional groups. It features a tert-butylsulfamoyl group, an aminoethyl group, multiple oxadiazol-3-yl groups, and a 3-bromo-4-fluorophenyl group. This unique molecular structure suggests potential interactions with biological targets, making it a compound of interest for further research and development.
Uses
Used in Pharmaceutical Industry:
(Ν-(2-((4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-yl)amino)ethyl)tert-butylsulfamoyl)carbamate is used as a potential candidate for drug development due to its unique molecular structure that may allow for interactions with various biological targets.
Further research and testing would be necessary to determine the specific properties, potential therapeutic applications, and any possible side effects of this compound. The pharmaceutical industry may explore its use in the development of new drugs targeting a range of diseases or conditions, depending on the outcomes of these investigations.
Check Digit Verification of cas no
The CAS Registry Mumber 1204669-69-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,4,6,6 and 9 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1204669-69:
(9*1)+(8*2)+(7*0)+(6*4)+(5*6)+(4*6)+(3*9)+(2*6)+(1*9)=151
151 % 10 = 1
So 1204669-69-1 is a valid CAS Registry Number.
1204669-69-1Relevant articles and documents
Preparation method of IDO1 inhibitor Epacadostat intermediate
-
, (2018/06/26)
The invention relates to the drug synthesis field, specifically to a preparation method of an IDO1 (indoleamine-2, 3-dioxygenase 1) inhibitor Epacadostat intermediate 4-(3-bromo-4-fluorophenyl)-3-(4-((2-bromoethyl)amino)-1, 2, 5-oxadiazole-3-yl)-1, 2, 4-o
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
-
, (2016/05/24)
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER
-
, (2014/05/24)
In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inven
